The enduring proliferation of CML stem cells expressing BCR-ABL1 fusion proteins eventually potentiates the occurrence of additional mutations, which are often associated with a more negative prognosis and the eventual development of resistance to clinical treatments [7,8]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.